Comparing SG&A Expenses: AbbVie Inc. vs Catalent, Inc. Trends and Insights

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving pharmaceutical and biotechnology sectors, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants: AbbVie Inc. and Catalent, Inc., from 2014 to 2023. AbbVie, a leader in the pharmaceutical industry, has seen its SG&A expenses grow by approximately 66% over the decade, peaking in 2022. In contrast, Catalent, a key player in drug development and delivery, experienced a more modest increase of around 180% in the same period, reflecting its strategic expansions.

While AbbVie's expenses surged in 2020, coinciding with its acquisition of Allergan, Catalent's steady rise highlights its consistent growth strategy. Notably, 2024 data for AbbVie is missing, indicating potential reporting delays or strategic shifts. These insights underscore the dynamic nature of financial management in the pharmaceutical sector.